Valuence Merger I Amends Proxy to Extend Termination Deadline into 2026

Valuence Merger I in an amended proxy said it has adjusted a proposed deadline extension to run until March 3, 2026, rather than a deadline of September 2025 as outlined in the initial proxy filing.

Valuence I lost more than two-thirds of its shares outstanding to redemptions in connection with the last extension vote a year ago.

The SPAC completed a $200 million IPO in March 2022. Since then, it has focused on life sciences targets based in Asia, though excluding China, Hong Kong and Macau. Valuence I has yet to announce a deal. Read more.

Total
0
Shares
Related Posts
IPO
Read More

BYTE Acquisition Files for $300M IPO

The SPAC in the filing said it will search for targets in the Israeli technology industry, including those engaged in cybersecurity, automotive technology, fintech, enterprise software, cloud computing, semiconductors, medical technology, AI and robotics.